| $376M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $99M |
Buys | $0 | 0 | 0 |
Sells | $21,974,521 | 19 | 100 |
| Martini Gregory S. | Chief Financial Officer | 0 | $0 | 3 | $82,951 | $-82,951 |
| Gaskins Tammi L | Chief Commercial Officer | 0 | $0 | 4 | $101,407 | $-101,407 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 0 | $0 | 2 | $121,586 | $-121,586 |
| John Minardo | Chief Legal Officer | 0 | $0 | 3 | $142,690 | $-142,690 |
| Silver Ronald | Principal Accounting Officer | 0 | $0 | 4 | $255,510 | $-255,510 |
| MCCOURT Thomas A | Chief Executive Officer | 0 | $0 | 2 | $739,929 | $-739,929 |
| DENNER ALEXANDER J | director | 0 | $0 | 1 | $20.53M | $-20.53M |
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Over the last 12 months, insiders at Ironwood Pharmaceuticals, Inc. have bought $0 and sold $21.97M worth of Ironwood Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ironwood Pharmaceuticals, Inc. have bought $460,539 and sold $8.38M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,920 shares for transaction amount of $60,204 was made by Duane Jon R (director) on 2024‑03‑06.
| 2026-03-17 | Sale | DENNER ALEXANDER J | director | 6.73M 3.8741% | $3.05 | $20.53M | +12.92% | |
| 2026-02-24 | Sale | MCCOURT Thomas A | Chief Executive Officer | 103,526 0.0615% | $3.66 | $378,905 | -3.96% | |
| 2026-02-24 | Sale | Shetzline Michael | SVP, CMO, Head-Res&Drug | 17,012 0.0101% | $3.66 | $62,264 | -3.96% | |
| 2026-02-24 | Sale | John Minardo | Chief Legal Officer | 19,053 0.0113% | $3.66 | $69,734 | -3.96% | |
| 2026-02-24 | Sale | Silver Ronald | Principal Accounting Officer | 12,621 0.0075% | $3.66 | $46,193 | -3.96% | |
| 2026-02-24 | Sale | Gaskins Tammi L | Chief Commercial Officer | 11,239 0.0067% | $3.66 | $41,135 | -3.96% | |
| 2026-02-24 | Sale | Martini Gregory S. | Chief Financial Officer | 11,457 0.0068% | $3.66 | $41,933 | -3.96% | |
| 2026-02-23 | Sale | MCCOURT Thomas A | Chief Executive Officer | 94,757 0.0592% | $3.81 | $361,024 | -2.80% | |
| 2026-02-23 | Sale | Shetzline Michael | SVP, CMO, Head-Res&Drug | 15,570 0.0097% | $3.81 | $59,322 | -2.80% | |
| 2026-02-23 | Sale | John Minardo | Chief Legal Officer | 17,439 0.0109% | $3.81 | $66,443 | -2.80% | |
| 2026-02-23 | Sale | Silver Ronald | Principal Accounting Officer | 11,552 0.0072% | $3.81 | $44,013 | -2.80% | |
| 2026-02-23 | Sale | Gaskins Tammi L | Chief Commercial Officer | 10,287 0.0064% | $3.81 | $39,193 | -2.80% | |
| 2026-02-23 | Sale | Martini Gregory S. | Chief Financial Officer | 10,487 0.0065% | $3.81 | $39,955 | -2.80% | |
| 2026-01-05 | Sale | Silver Ronald | Principal Accounting Officer | 35,416 0.0218% | $4.60 | $162,914 | -15.03% | |
| 2025-11-17 | Sale | Gaskins Tammi L | Chief Commercial Officer | 6,016 0.0039% | $3.32 | $19,973 | +17.57% | |
| 2025-08-11 | Sale | John Minardo | Chief Legal Officer | 7,754 0.0048% | $0.84 | $6,513 | +309.23% | |
| 2025-08-11 | Sale | Silver Ronald | Principal Accounting Officer | 2,846 0.0018% | $0.84 | $2,391 | +309.23% | |
| 2025-08-11 | Sale | Gaskins Tammi L | Chief Commercial Officer | 1,316 0.0008% | $0.84 | $1,105 | +309.23% | |
| 2025-08-11 | Sale | Martini Gregory S. | Chief Financial Officer | 1,265 0.0008% | $0.84 | $1,063 | +309.23% | |
| 2025-05-16 | Sale | MCCOURT Thomas A | Chief Executive Officer | 13,353 0.0084% | $0.58 | $7,745 | +435.09% |
| DENNER ALEXANDER J | director | 9188635 5.582% | $33.35M | 8 | 1 | +18.72% |
| MCCOURT Thomas A | Chief Executive Officer | 1489002 0.9045% | $5.41M | 0 | 37 | |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 521425 0.3168% | $1.89M | 0 | 13 | |
| John Minardo | Chief Legal Officer | 363886 0.2211% | $1.32M | 0 | 11 | |
| Silver Ronald | Principal Accounting Officer | 252636 0.1535% | $917,068.68 | 0 | 17 | |
| Gaskins Tammi L | Chief Commercial Officer | 213738 0.1298% | $775,868.94 | 0 | 5 | |
| Martini Gregory S. | Chief Financial Officer | 160601 0.0976% | $582,981.63 | 0 | 4 | |
| Ridgeback Capital Investments L.P. | 10 percent owner | 6842839 4.1569% | $24.84M | 3 | 42 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 4696917 2.8533% | $17.05M | 1 | 16 | +9.03% |
| FMR LLC | 10 percent owner | 837736 0.5089% | $3.04M | 0 | 43 | |
| Currie Mark G | 521758 0.317% | $1.89M | 0 | 37 | ||
| Mallon Mark | Chief Executive Officer | 470605 0.2859% | $1.71M | 0 | 4 | |
| Consylman Gina | SVP, CFO & Treasurer | 336244 0.2043% | $1.22M | 0 | 17 | |
| Rickard Jason | SVP, Chief Operating Officer | 332648 0.2021% | $1.21M | 0 | 15 | |
| Emany Sravan Kumar | SVP, COO and CFO | 309572 0.1881% | $1.12M | 2 | 2 | <0.0001% |
| Higgins Michael J | Chief Operating Officer | 300000 0.1822% | $1.09M | 0 | 7 | |
| Davis Andrew | SVP, Chief Business Officer | 284685 0.1729% | $1.03M | 0 | 8 | |
| Gilbert Halley E | Chief Admin Officer & SVP | 265991 0.1616% | $965,547.33 | 0 | 14 | |
| Owens Edward P | director | 218954 0.133% | $794,803.02 | 4 | 0 | +34.25% |
| McHugh Julie | director | 139528 0.0848% | $506,486.64 | 0 | 12 | |
| Kilroy Conor | SVP, GC & Secretary | 122336 0.0743% | $444,079.68 | 0 | 3 | |
| Duane Jon R | director | 121028 0.0735% | $439,331.64 | 1 | 0 | <0.0001% |
| Kessler Marla L | director | 96572 0.0587% | $350,556.36 | 0 | 2 | |
| MacDonald Kelly | Chief Accounting Officer | 93041 0.0565% | $337,738.83 | 0 | 9 | |
| OLANOFF LAWRENCE S | director | 68629 0.0417% | $249,123.27 | 0 | 17 | |
| Moukheibir Catherine | director | 48633 0.0295% | $176,537.79 | 0 | 2 | |
| COOK JOSEPH C JR | director | 42775 0.026% | $155,273.25 | 0 | 6 | |
| Graney Thomas | Chief Financial Officer | 20763 0.0126% | $75,369.69 | 0 | 2 | |
| Fanucci Marsha | director | 19778 0.012% | $71,794.14 | 1 | 1 | <0.0001% |
| MCGUIRE TERRANCE | director | 0 0% | $0 | 0 | 1 | |
| ROBERTS BRYAN E | director | 0 0% | $0 | 0 | 13 |
$218,350,131 | 64 | 16.68% | $654.91M | |
$130,585,319 | 59 | 26.38% | $306.25M | |
$102,709,455 | 46 | 30.55% | $918.87M | |
$33,884,330 | 45 | 12.56% | $309.13M | |
$97,642,477 | 41 | -10.58% | $428.71M | |
$11,542,910 | 40 | 56.19% | $1.4B | |
$73,406,903 | 39 | -5.33% | $1.51B | |
$6,021,989 | 30 | -0.17% | $418.08M | |
$32,539,771 | 28 | 33.37% | $235.9M | |
$6,506,230 | 27 | -16.20% | $1.03B | |
Ironwood Pharmaceuticals, Inc. (IRWD) | $25,034,841 | 20 | 9.38% | $597.55M |
$1,843,996 | 10 | 22.92% | $905.23M | |
$26,633,903 | 9 | 42.23% | $1.11B | |
$758,061 | 9 | 60.03% | $172.56M | |
$1,718,514 | 9 | 38.13% | $612.37M | |
$529,315 | 8 | 7.33% | $432.89M | |
$721,578 | 7 | -19.64% | $182.73M | |
$725,133 | 7 | 30.62% | $1.27B | |
$12,300,713 | 4 | 24.14% | $211.93M |
| Increased Positions | 121 | +71.6% | 19M | +12.67% |
| Decreased Positions | 68 | -40.24% | 13M | -8.57% |
| New Positions | 59 | New | 9M | New |
| Sold Out Positions | 20 | Sold Out | 7M | Sold Out |
| Total Postitions | 222 | +31.36% | 155M | +4.1% |
| Armistice Capital, Llc | $68,961.00 | 9.91% | 16.15M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $68,627.00 | 9.86% | 16.07M | -130,123 | -0.8% | 2025-09-30 |
| Sarissa Capital Management Lp | $67,976.00 | 9.77% | 15.92M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $51,507.00 | 7.4% | 12.06M | +39,560 | +0.33% | 2025-09-30 |
| Bank Of America Corp /De/ | $49,940.00 | 7.18% | 11.7M | +8M | +248.3% | 2025-09-30 |
| Renaissance Technologies Llc | $35,664.00 | 5.12% | 8.35M | -53,996 | -0.64% | 2025-09-30 |
| Acadian Asset Management Llc | $27,766.00 | 3.99% | 6.5M | -47,194 | -0.72% | 2025-09-30 |
| Kynam Capital Management, Lp | $23,343.00 | 3.35% | 5.47M | 0 | 0% | 2025-09-30 |
| Aqr Capital Management Llc | $22,966.00 | 3.3% | 5.38M | -787,102 | -12.77% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $20,997.00 | 3.02% | 4.92M | +1M | +34.2% | 2025-09-30 |